Reflections on a 10-Year Journey in the Microbiome

Following a fortuitous path, researcher Aaron Cowley established expertise in process development for live biotherapeutic products at his company Captozyme. Today, as part of CDMO Arranta Bio, he is looking forward to helping drug developers bring the first microbiome-based therapies to the market.

Dr. Aaron B. Cowley is the chief scientific officer at Arranta Bio, having been a co-founder and the chief technical officer of Captozyme, which served the microbiome CDMO market for 10 years since 2009 and merged with Arranta Bio in November 2019. Captozyme’s enzyme therapeutic assets were spun out as a newly formed biopharmaceutical company, Oxidien Pharmaceuticals, LLC, a UF Innovate | The Hub resident client, to continue clinical development under the leadership of Captozyme’s outgoing chief executive officer, Helena Cowley.

He was the recipient of the prestigious Ruth L. Kirschstein National Research Service Award for his post-doctoral work at the University of Georgia. He holds a bachelor’s degree in biochemistry from Benedictine College, a Ph.D. in inorganic chemistry from the University of Kansas, and an MBA from the University of Florida.

Learn more about Reflections on a 10-Year Journey in the Microbiome.